Scipher Medicine is broadening its precision medicine efforts beyond diagnostics. After leadership changes, the company is leveraging its extensive collection of non-oncology transcriptomic data to spur biomarker discovery and drug development tools, particularly in immunology. Recent partnerships, including one with Savant Bio, will enhance clinicogenomic datasets in rheumatoid arthritis using AI to extract structured clinical variables from free-text physician notes. Scipher aims to emulate oncology-focused platforms by integrating broad omics data for clinical testing and therapeutic discovery, addressing knowledge gaps in fields outside of cancer. Expansion efforts also include deals with pharma and informatics companies to drive personalized medicine development across multiple disease areas.